Epidemiologic studies show that the risk of adverse cardiovascular outcomes increases progressively with increasing blood pressure (BP), whereas clinical trials demonstrate that lowering BP reduces such risk. 1 All antihypertensive medications lower BP, but specific drug classes have pleiotropic effects that may contribute to cardiovascular risk reduction. The relative importance of the degree of BP reduction vs. the mechanisms associated with BP reduction remains the subject of considerable debate. 2 The primary purpose of antihypertensive therapy is BP reduction, and this continues to be the accepted basis for their clinical benefit. Developing a better understanding of the mechanisms underlying hypertensive vascular disease, as well as the pleiotropic actions of antihypertensive agents, offers the potential for more targeted therapy that reduces global cardiovascular risk.
The pressure wave in the aorta reflects the summation of a forward wave generated by ejection of blood from the left ventricle and a reflected wave arriving subsequently from the periphery (Figure 1) . 10 Due to the elasticity of the central arteries, only a portion of each stroke volume is delivered distally during systole, with the remainder delivered by elastic recoil of the aorta during diastole. 10 Increases in central arterial stiffness result in the delivery of greater portions of each stroke volume during systole. As a result, the velocities of both forward and reflected waves increase, and the reflected wave returns earlier to the aorta, thereby raising central aortic pressure and increasing left ventricular load. Accordingly, central aortic stiffness contributes directly to the generation of a wide pulse pressure with higher systolic BP (SBP) and lower diastolic BP.
The mechanism by which central aortic stiffness contributes to higher pulse pressure was evaluated in patients with uncomplicated systolic hypertension by calibrated tonometry and pulsed Doppler. 12 Hypertensive patients had significantly higher pulse pressure than age-and gender-matched normotensive controls, an effect attributed primarily to a higher characteristic impedance (Z c ). The Z c value represents the pressure generated by the forward wave in the proximal aorta during early systole before the return of the reflected wave. Unlike pulse wave velocity, the sensitivity of Z c is amplified by a decrease in lumen diameter. Pulse wave velocity and Z c values, inserted into the water hammer (surge) equation, showed that mean effective aortic diameter was decreased in hypertensive subjects as compared with normotensive controls. Thus, an increase in pulse pressure is disproportionate to the increase in mean arterial pressure in patients with systolic hypertension due to increased Z c and reduced effective aortic diameter.
enDothelial DysfunCtion in CarDioVasCular Disease: a target for Combination treatment
The endothelium is a continuous layer of cells that cover the luminal vessel walls. These cells produce a variety of signaling molecules that modulate vascular tone and inflammatory processes. Perhaps the most important molecule is NO, produced by endothelial NO synthase (eNOS), an NAD(P)H-dependent enzyme. Beyond vasodilation, NO inhibits smooth muscle cell proliferation and migration, adhesion of leukocytes to the endothelium, and platelet aggregation. 13 Vascular injury, metabolic disorders, and deficiencies in essential substrate (l-arginine) and cofactors (e.g., tetrahydrobiopterin) contribute to "uncoupling" of eNOS and loss of NO bioavailability (Figure 2 ). 14 Thus, endothelial dysfunction has been causally linked to atherosclerosis and its clinical manifestations.
Cardiovascular agents modify endothelial function through processes that may be, in part, unrelated to their primary pharmacologic target of action. Drugs that improve vascular NO levels include nitrates, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARBs), CCBs, and HMG-CoA reductase inhibitors (statins). These agents represent two broad classes of compounds-those that release NO or one of its redox analogs spontaneously and those that require enzymatic metabolism to generate NO. By inhibiting ACE activity, for example, ACE inhibitors influence the levels of angiotensin II and bradykinin within the vascular wall while statins upregulate eNOS expression (Figure 3) . 15, 16 Hypertension NO synthesis figure 1 | components of central aortic pressure. In this typical aortic pulse contour, P1 is the pressure peak caused by the forward flow wave; AP is the late systolic augmentation pressure caused by return of the reflected wave to the aortic root; and P2 is the pressure peak that results from summation of the forward and reflected waves. DN is the dicrotic notch dividing systole and diastole. the augmentation index (AI) is defined as the ratio of AP to pulse pressure (PP). DbP, diastolic blood pressue; MAP, mean arterial pressure; SbP, systolic blood pressure. Adapted with permission from ref. 11 .
role of neurohormonal anD PhysiologiC meChanisms in VasCular Disease renin-angiotensin-aldosterone system
The RAS plays a central role in the short-and long-term regulation of BP, as well as in the regulation of fluid and electrolyte balance. In vascular disease, activation of the RAS also promotes arterial remodeling and inflammation, further contributing to progressive vascular and renal dysfunction. 6 The binding of angiotensin II to AT 1 receptors on vascular smooth muscle cells promotes vasoconstriction while simultaneously stimulating aldosterone secretion from the adrenal cortex and sodium reabsorption in renal proximal tubules. AT 1 activation also facilitates sympathetic neurotransmission. 17 Beyond its genomic effects on volume regulation, recent studies indicate that aldosterone contributes to hypertension through enhanced restriction of renal afferent arterioles-an effect that is augmented with inhibitors of endothelial-dependent NO release. 18 The vasoconstrictive effects of aldosterone, for example, were reduced by inhibiting protein kinase C-or IP 3 -induced calcium release, indicating that aldosterone promotes vasoconstriction by mobilizing intracellular calcium stores. 18 In addition, the interaction of angiotensin II with AT 1 receptors on endothelial cells, vascular smooth muscle cells, and leukocytes activates signal transduction mechanisms that promote oxidative stress, inflammation, cell proliferation, and fibrosis. 6, 19 Angiotensin II activates NAD(P)H oxidase in endothelial and vascular smooth muscle cells, which stimulates production of reactive oxygen species. 19 Angiotensin II also increases the activity of the proinflammatory transcription factor nuclear factor−κB, which controls expression of inflammatory cytokines. Finally, angiotensin II stimulates growth factors, extracellular proteins, and matrix metalloproteinases, thereby promoting proliferative and fibrotic mechanisms involved in vascular remodeling. 17 The interaction of angiotensin II with AT 2 receptors appears to counteract some of the effects mediated by the AT 1 receptor.
More important, angiotensin II binding to AT 2 stimulates NO release, promoting normal endothelial function and antiinflammatory activity. 20 
hypertension and endothelial dysfunction
Endothelial dysfunction and reduced NO bioactivity are associated with hypertension as shown in a recent study in which forearm blood flow was measured by strain-gauge plethysmography after infusion with the endothelium-dependent and endothelium-independent vasodilators, that is, acetylcholine and sodium nitroprusside, respectively. 21 Vasodilation in response to acetylcholine, but not to nitroprusside, was significantly reduced in patients with hypertension compared with control subjects, thus indicating an endothelial-dependent pathway. Endothelial dysfunction increased with age in both hypertensive and normotensive patients in this study.
The cellular mechanisms that contribute to endothelial dysfunction in hypertension have been characterized in experimental models of the disease. In stroke-prone spontaneously hypertensive rats, there is a pronounced loss in NO bioavailability despite increased eNOS levels. 22 A similar change in eNOS expression, as well as an increase in O 2 − and ONOO − generation, was observed in normal rats that were made hypertensive by surgical procedures such as aortic banding. 23 The basis for this paradox is attributed to eNOS uncoupling mechanisms. 24, 25 Endothelial dysfunction is more common in African Americans than whites, which may reflect reduced NO production in African Americans. 26 Nebivolol, a β-blocker with antioxidant properties, reduced superoxide and peroxynitrite levels and restored NO bioavailability in endothelial cells from African-American donors to levels observed in cells from white donors. 27 Thus, blocking reactive oxygen species offers the potential to improve NO release. It should be noted that in some of the aforementioned studies, investigators used suprapharmacologic treatment levels; however, these studies still provide important insights into potential new areas of clinical intervention. at least three other cardiovascular risk factors were assigned to amlodipine plus perindopril as needed or atenolol plus bendroflumethiazide as needed to achieve BP targets, 29 central aortic pressure and hemodynamic variables were assessed by radial artery applanation tonometry and pulse wave analysis in 2,199 patients for up to 4 years. 28 Nearly all patients (95%) received at least two antihypertensive agents, with 56 and 60% of subjects in the CCB/ACE inhibitor and β-blocker/diuretic groups, respectively, receiving their predefined combination. Both regimens produced similar reductions in brachial SBP (P = 0.2) (Figure 4) . However, the CCB-based regimen produced significantly greater reductions in central aortic SBP (4.3 mm Hg; 95% confidence interval, 3.3-5.4 mm Hg; P < 0.0001) and central aortic pulse pressure (3.0 mm Hg; 95% confidence interval, 2.1-3.9 mm Hg; P < 0.0001) than the β-blocker-based regimen. Notably, differences between brachial and central aortic BP values persisted throughout the follow-up period. Higher central aortic SBP and pulse pressure with atenolol-based treatment was primarily attributable to greater wave reflection (augmentation index) than to differences in the forward wave following ejection from the left ventricle. Post hoc analysis of the CAFE data provided additional information about the relationship between the effect of treatment on central aortic pressure and patient outcomes. Central aortic pulse pressure, central aortic wave augmentation, forward pressure wave height, and brachial pulse pressure correlated significantly with the composite end point of cardiovascular events/procedures and development of renal impairment. 28 After adjustment for age and baseline risk factors, central aortic pulse pressure remained significantly associated with the composite end point.
Calcium channel and RAS blockade improve vessel wall elasticity and reduce arterial stiffness. In hypertensive patients, treatment with CCBs or ACE inhibitors significantly reduced the central aortic augmentation index, consistent with a reduction in arterial stiffness. 30, 31 In healthy volunteers, infusion of angiotensin II significantly increased the augmentation index, whereas infusion of the vasodilator nitroglycerin reduced the augmentation index. 32 In a crossover study of untreated hypertensive patients, bisoprolol produced a greater reduction in brachial SBP than amlodipine, lisinopril, doxazosin, or bendroflumethiazide, but increased the central aortic augmentation index; 33 each of the other drugs reduced the augmentation index. Similarly, in elderly patients with elevated SBP, β-blockers increased the augmentation index and augmented aortic SBP, whereas CCBs, ACE inhibitors, and diuretics lowered these parameters. 34 CCb and ras blockade in cardiovascular disease: biochemical and physiologic effects Long-acting CCBs, such as the highly lipophilic amlodipine, exert antioxidant effects that protect LDL and membrane lipids. Amlodipine exists in a charged state under physiologic conditions, which enables it to strongly interact with cell membrane phospholipids. 35, 36 The antioxidant effects of amlodipine appear to be independent of calcium channel modulation ( Figure 5 ). 35 The antioxidant activity of amlodipine has been observed in animal models. 37 In coronary microvessels isolated from canine cardiac tissue, amlodipine caused a dose-dependent release of nitrite, the hydration product of NO. 38 The effects of amlodipine on both nitrite release and the NO-dependent regulation of cardiac oxygen consumption were inhibited with specific antagonists of eNOS. By contrast, the addition of other dihydropyridinetype CCBs (nifedipine) and a non-dihydropyridine analog (diltiazem) failed to reproduce this activity. The effects of amlodipine were similar in magnitude to those observed with ACE inhibitors. 39 Amlodipine also inhibited cytokine-induced apoptosis of endothelial cells and protected against excessive cell loss due to apoptosis in cultured cerebellar granule cells. 40 The benefit of amlodipine therapy in patients with established coronary artery disease has been suggested in several clinical trials. In the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT), a study comprised of 825 patients with angiographically documented coronary artery disease, 41 amlodipine significantly slowed carotid artery atherosclerosis. Amlodipine was associated with fewer cases of unstable angina pectoris and coronary revascularization procedures.
The Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) study evaluated the effects of amlodipine and enalapril on cardiovascular events in 1991 normotensive patients with angiographically documented coronary artery disease. 42 Amlodipine reduced the risk of cardiovascular events which was attributable to reductions in coronary revascularization procedures and hospitalizations for angina pectoris. In a substudy of CAMELOT, conducted to assess the progression of coronary atherosclerosis by intravascular ultrasound, amlodipine reduced the change in atheroma volume, with significantly less progression observed in the subgroup with SBP values above the mean (0.2% vs. 2.3%; P = 0.02).
The effect of amlodipine in patients aged ≥55 years with hypertension and at least one other coronary heart disease risk factor was evaluated in the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT). 43 Amlodipine was compared to lisinopril and a thiazide diuretic in 33,357 patients. A review of outcomes showed the rate of combined fatal coronary heart disease or nonfatal myocardial infarction in the amlodipine and lisinopril groups was not significantly different from that in the thiazide group. This trial led to the recommendation that diuretics be used as first-line therapy for uncomplicated hypertension despite the observed higher rates of hypokalemia and new onset diabetes.
RAS blockade with ACE inhibitors or ARBs exerts numerous antiatherogenic effects that interrupt the vascular disease process. In a randomized, active-controlled trial of patients with essential hypertension, treatment with an ARB significantly improved the vasoconstrictive response to l-NMMA, indicating an increase in basal NO production, whereas diuretic treatment had no effect despite similar BP reductions. 44 RAS blockade also significantly decreased markers of monocyte and endothelial cell activation in hypertensive patients with type 2 diabetes. 45 In a study of patients with coronary artery disease, treatment with an ACE inhibitor or ARB significantly increased flow-mediated vasodilation, primarily due to increased NO bioavailability. 46 In addition to RAS blockade, AT 1 receptor antagonists confer distinct atheroprotective benefits by allowing stimulation of unblocked AT 2 receptors. Several reports have shown that AT 1 receptor antagonism reduces endothelial dysfunction by improving basal NO synthesis. Valsartan reduced intimal thickening in hypercholesteremic rabbits, 47 and both valsartan and losartan stimulated NO release from platelets and endothelial cells, resulting in inhibition of platelet adhesion and aggregation. 48 Other studies showed that candesartan-induced eNOS augmentation was abolished by a specific AT 2 receptor antagonist, consistent with AT 2 receptor-mediated NO release. 49 In coronary arteries, activation of AT 1 receptors by a low concentration of angiotensin II caused vasoconstriction by increasing NAD(P)H oxidase superoxide production. By contrast, higher concentrations of angiotensin II caused vasodilatation by activating AT 2 receptors through enhanced NO bioavailability (Figure 3) . 50 RAS blockade also produces antiatherogenic and antiinflammatory effects. In animal models of hypercholesterolemia, treatment with valsartan or benazepril decreased the intimal lesion area, increased the lumen area, and decreased macrophage proliferation. 47, 51 In a recent study, RAS blockade decreased the release of proinflammatory cytokines, IL-6 and TNF-α, from leukocytes. 52 In a large randomized trial of patients with stage 2 hypertension, treatment with an ARB significantly reduced levels of high-sensitivity C-reactive protein as compared with an ARB/diuretic combination, despite greater BP reductions with the combination. 53 
effects of CCb and ras blockade in cerebrovascular disease
Hypertension is the overwhelming risk factor for cerebrovascular disease and its clinical manifestations such as stroke, cognitive decline, and dementia. Any of the commonly used antihypertensive drugs lower the incidence of stroke, with larger reductions in BP resulting in larger reductions in risks. Some clinical data have suggested advantages for ACE inhibitors, ARBs, and CCBs.
The prospective randomized Losartan Intervention For Endpoint Reduction (LIFE) trial showed a significant difference in stroke rate in favor of the ARB (losartan) compared with atenolol despite similar reductions in BP. 54 Even the role of hypertension and its treatment remain controversial as the Acute Candesartan Cilexetil Therapy in Stroke Survivors (ACCESS) trial suggested that candesartan is safe in hypertensive acute stroke patients and offers advantages independent from BP control. 55 In the Heart Outcomes Prevention Evaluation (HOPE) trial, the ACE inhibitor ramipril reduced the occurrence number of primary stroke by 32% compared with placebo. 56 In the Perindopril Protection Against Recurrent Stroke Study (PROGRESS) trial, combination therapy with ACE inhibitor (perindopril) and indapamide reduced the risk of stroke among both hypertensive and normotensive patients with a history of stroke or transient ischemic attack. 57 Larger BP reductions were associated with the risk reductions in the active regimen group. A substudy analysis also showed a lower frequency of cognitive decline among patients undergoing active therapy with perindopril and indapamide. 58 The brain possesses the same RAS as the systemic circulation. [59] [60] [61] Angiotensin II plays a pathophysiologic role in the development of ischemic stroke, and inhibition of the RAS reduces the risk of stroke in a manner independent from alterations of systemic BP. Activation of AT 1 receptors by angiotensin II contributes to vasoconstriction, vascular proliferation, and inflammation leading to cerebrovascular insufficiency as well as disruption of the blood-brain barrier. ARBs which selectively block AT 1 receptors, decrease local vasoconstriction, and allow free angiotensin II to stimulate unoccupied AT 2 receptors, which alleviates local brain ischemia and reduces the extent of tissue loss. 62, 63 The protective effects of ARBs may be superior to that of ACE inhibitors due to the differential activation of AT 2 receptors. Many neuronal processes are regulated by calcium influx through voltage-sensitive calcium channels, including protein phosphorylation, gene expression, neurotransmitter release, and modulation of action potential firing pattern. 64 Consistent with these experimental data, CCBs have been shown to have cerebrovascular protective effects in clinical trials. In the Systolic Hypertension in Europe (Syst-Eur) trial, a nitrendipine-based regimen significantly lowered the frequency of fatal and nonfatal stroke compared with placebo and contributed to a reduction in both vascular and Alzheimer's-type dementia. 65, 66 The Nordic Diltiazem (NORDIL) trial, which compared the effects of diltiazem with diuretics or β-blockers, or combination of diuretic and β-blockers, the diltiazem regimen was more effective than the combined diuretic and β-blocker regimen in lowering the rate of all strokes beyond BP lowering, even though the mean reductions in diastolic pressure were identical in the two groups and the reduction of SBP was greater in the diuretic/β-blocker group (20.3/18.7 mm Hg in the diltiazem group vs. 23.3/18.7 mm Hg in the diuretic/β-blocker group). 67 However, in the Intervention as a Goal in Hypertension Treatment (INSIGHT) trial, nifedipine and coamilodzide (a thiazide diuretic) were equally effective in preventing overall cardiovascular or cerebrovascular complications. 68 The cerebrovascular-protective effects of both RAS and CCBs are attributed to their pleiotropic properties. In the recent Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA), older antihypertensive agents (β-blockers and diuretics) were compared with newer antihypertensive drugs (the CCB, amlodipine, and the ACE inhibitor, perindopril). The results showed significant advantage for the CCB/ACE inhibitor combination in lowering stroke frequency. 69 In the ASCOT lipid-lowering arm, there was evidence of a further advantage for patients on a lipophilic statin (atorvastatin) when used in combination with the CCB/ ACE inhibitor combination, as compared to the β-blocker/ diuretic regimen. 70 The basis for this benefit may be due to synergistic effects with atorvastatin on endothelial-dependent NO release and reactive oxygen species mechanisms. 71 rationale for CalCium Channel/ras bloCkaDe Combination theraPy
Certain lipophilic CCBs and RAS antagonists have ancillary and synergistic effects that enhance NO bioavailability, reduce oxidative stress, and suppress inflammatory responses. Evidence from preclinical and clinical studies suggests that the complementary mechanisms of these drug classes provide greater efficacy when used in combination. The pleiotropic effects of RAS and CCBs on the mechanisms underlying hypertensive vascular disease, coupled with the efficacy of combination therapy on reducing central aortic pressure, indicate the beneficial effects that this combination has on patient outcomes.
Angiotensin II is a major mediator of oxidative stress, reducing NO activity by NAD(P)H oxidase activation, resulting in the production of the superoxide anion. This molecule also contributes to inward calcium current modulation in the failing heart. 72 In atrial fibrillation, calcium influx via L-voltagesensitive calcium channels plays a crucial role in atrial excitation-contraction coupling. 73 Angiotensin II increases transcription of the α1C subunit of L-voltage-sensitive calcium channels in atrial myocyte, while losartan and simvastatin, which inhibit NAD(P)H oxidase activity and reactive oxygen species generation, attenuate L-voltage-sensitive calcium channel current. [74] [75] [76] These data suggest that combining calcium channel and RAS blockade may be more effective than monotherapy. In a cuff-induced vascular injury model, coadministration of azelnidipine and olmesartan at nonhypotensive doses significantly inhibited VSMC proliferation and neointimal formation in wild-type mice, while azelnidipine or olmesartan alone at these lower doses did not affect neointimal formation. 77 In Dahl salt-sensitive rats, the animals developed hypertension, aortic hypertrophy, proteinuria, and endothelial dysfunction. 78 Amlodipine (10 mg/kg/day) significantly reduced SBP, aortic hypertrophy, and proteinuria, whereas benazepril (40 mg/kg/day) significantly reduced proteinuria without significantly lowering SBP. The CCB/ACE inhibitor combination was more effective than monotherapy, normalizing SBP and proteinuria. Moreover, both the CCB and the ACE inhibitor alone significantly improved endothelial-dependent relaxation. Comparable results were seen in a myocardial infarction model in rats. 79 Five weeks after occlusion of the left anterior descending artery, cardiac interstitial fluid levels of NO metabolites and inflammatory mediators were measured. Cardiac ischemia substantially reduced NO levels, but treatment with amlodipine restored NO levels (Figure 6) . Treatment with benazepril also increased NO levels, although to a lesser extent. When the CCB and ACE inhibitor were administered in combination, NO levels were further increased. In contrast, treatment with hydrochlorothiazide did not affect NO or inflammatory mediator levels.
Clinical studies show that the combination of amlodipine and an RAS blocker produces significantly greater reductions in BP than either agent alone. [80] [81] [82] [83] In a randomized, crossover trial of hypertensive patients with type 2 diabetes, amlodipine treatment significantly increased tissue plasminogen activator (t-PA) activity with no effect on plasma plasminogen activator inhibitor-1 (PAI-1) activity while the ACE inhibitor benazepril significantly decreased PAI-1 activity with no effect on t-PA activity; however, combination therapy resulted in both a significant increase in t-PA activity and a significant decrease in PAI-1 activity. 84 In hypertensive patients with at least one additional risk factor for endothelial dysfunction, amlodipine/benazepril combination treatment vs. amlodipine significantly increased flow-mediated vasodilation. 85 These findings suggest that combining a CCB with an ACE inhibitor may improve endothelial function and slow the atherogenic process. In addition, preliminary results released from the recent Avoiding Cardiovascular Events through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) study demonstrated superiority for the combination of amlodipine with an ACE inhibitor vs. a diuretic in reducing cardiovascular events, despite similar reductions in BP. This new trial, pending official publication, suggests a benefit for the CCB/ACE inhibitor combination.
ConClusions
Central arterial pressure, determined by cardiac output and peripheral vascular resistance, as well as by arterial stiffness and the timing and magnitude of pressure wave reflections, may be a stronger predictor of cardiovascular events and response to antihypertensive therapy than brachial BP. Calcium channel and RAS blockers have ancillary and synergistic properties that may contribute to their clinical benefit (Figure 7) . These drugs lower brachial BP to a similar extent as other antihypertensive agents, including diuretics and β-blockers. However, as shown in the CAFE study, a CCB/ACE inhibitor regimen produced significantly greater reductions in central aortic SBP and pulse pressure than a β-blocker/diuretic regimen, despite comparable reductions in brachial SBP. 28 Moreover, CCBs, ACE inhibitors, and ARBs have been shown to reduce the central aortic augmentation index, consistent with a reduction in arterial stiffness. 30, 31, 33, 34 From a mechanistic perspective, CCBs and RAS blockers improve endothelial function and reduce oxidative stress and inflammation in the arterial vasculature. More important, these drug classes enhance the bioavailability of NO, which has vasodilatory properties and protects the endothelium from atherogenic and thrombotic stimuli. Because hypertensive patients have defects in endothelial function and NO production, these drugs offer the potential to further reduce vascular damage beyond that associated with BP lowering. A number of clinical trials have demonstrated the efficacy of these agents, in combination therapy, for lowering BP and improving clinical figure 6 | change in cardiac interstitial fluid levels of nitric oxide metabolites (NoX) at 5 weeks after occlusion of the left anterior descending artery. rats were treated with amlodipine 10 mg/kg/day, benazepril 40 mg/kg/day, a combination of amlodipine and benazepril, hydrochlorothiazide 3 mg/kg/day, or placebo (5% dextrose in water) starting 3 days after occlusion. *P < 0.05 vs. placebo, † P < 0.001 vs. placebo, and ‡ P < 0.01 vs. sham control. Adapted with permission from ref. 79 . Angiotensin II figure 7 | rationale for the combined use of calcium channel blocker (ccb) and renin-angiotensin system (rAS) inhibitors based on pathophysiologic processes associated with abnormal calcium influx and angiotensin II. rAAS, renin-angiotensin aldosterone system.
outcomes. Future study is needed to elucidate fully the potential of combination therapy for vascular protection.
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